Akorn (AKRX) Guides FY13 adj.-EPS Below Views, Revs In-Line; Reaffirms FY12

Article Related Press Releases (1) Stock Quotes (1) Comments (0)

Akorn, Inc. (NASDAQ: AKRX), a niche pharmaceutical company, today provided full year 2013 financial guidance. The Company’s guidance excludes the impact from any products for which the Company has not yet received FDA approval. The Company will provide a more detailed update during its year-end 2012 conference call.

Total revs of $325 million to $335 million. The Street is at $330.7 million.

SG&A expenses of $51 million to $54 million.

Adjusted net income per share of 57 cents to 61 cents. The Street is at 66 cents.

CapEx of about $25 million.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Actuant Corp. (ATU) Tops Q3 EPS by 3c; Trims FY13 Outlook, Guides FY14
• Carrizo Oil (CRZO) Boosts Q2, FY12 Production Outlook
• MeadWestvaco (MWV) Sees Lower Q2 Food and Beverage Profit

Create E-mail Alert Related Categories

Guidance, Hot Guidance

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?